Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. McDermott on Long-Term Benefit With Nivolumab in RCC

July 12th 2016

David F. McDermott, MD, associate professor of Medicine, Harvard Medical School, staff physician, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses long-term follow-up results of treatment with nivolumab (Opdivo) for patients with renal cell carcinoma (RCC).

Adjuvant Sunitinib Improves DFS in Renal Cell Carcinoma

July 9th 2016

Sunitinib (Sutent) extended disease-free survival versus placebo as an adjuvant therapy for patients with renal cell carcinoma at high risk of recurrence in the phase III S-TRAC trial.

Dr. Jorge Garcia on METEOR Trial for RCC

July 7th 2016

Jorge A. Garcia, MD, Department of Hematology and Oncology, discusses the results of the phase III METEOR trial, which compared the efficacy of cabozantinib (Cabometyx) versus everolimus (Afinitor) in patients with advanced renal cell carcinoma.

Dr. Nanus on Next Steps With Atezolizumab in Patients With mUC

July 7th 2016

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses the unanswered questions that remain with atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma (mUC).

GU Cancer Treatments Advance, But Their Application Remains Unclear

July 5th 2016

Even as our understanding of the biology of prostate and bladder cancers improves and treatment protocols are refined, there remain many clinical scenarios in which no clear-cut answers are available.

A Look to the Future in RCC

June 29th 2016

A Changing Landscape in RCC

June 29th 2016

Novel Approaches in Advanced RCC

June 29th 2016

Long-Term RCC Data with Nivolumab

June 29th 2016

Second and Third-Line Decisions in RCC

June 29th 2016

The Role of Lenvatinib in Advanced RCC

June 29th 2016

Options in the Third Line Setting for RCC

June 29th 2016

The Rationale for Cabozantinib in Advanced RCC

June 29th 2016

Patient Selection and Checkpoint Inhibition in RCC

June 29th 2016

Advanced RCC Sequencing Challenges

June 29th 2016

Assessing Treatment Response with RCC First-Line Therapies

June 29th 2016

RCC First-Line Toxicity Considerations

June 29th 2016

Choosing Among TKIs in Advanced RCC

June 29th 2016

Determining Initial Therapeutic Approach in Advanced RCC

June 29th 2016

Goals of Therapy in Advanced RCC

June 29th 2016